...all the core technology and preclinical programs of Intronn for an undisclosed amount of stock. Intronn's...
...The product is in Phase II testing to treat HIV. Further terms were not disclosed. Intronn Inc....

...Hired: Gerard McGarrity as EVP of scientific and clinical affairs, formerly president and CEO of Intronn Inc. WIR...

...levels. Data were presented at the American Society of Gene Therapy meeting in St. Louis. Intronn Inc....

...the Center for Biologic Evaluation and Research. Otto was previously COO of gene/cell therapy company Intronn...

...use its SMaRT spliceosome-mediated RNA trans-splicing technology in combination with Isogenis' veto gene delivery technology. Intronn Inc....

...allows the cell's own splicing mechanisms to replace the mutated portion with the corrected message. Intronn Inc....

...but noted that a different vector could be used to deliver the CFTR-PTM more effectively. Intronn Inc....

...Kidney Diseases to develop its SMaRT technology to repair the genetic defect in cystic fibrosis. Intronn...